Avicanna Latam SAS, a subsidiary of Avicanna Inc., has launched the re+play CBD wellness brand across the United States in partnership with Harrington Wellness. The initial lineup comprises a 3% CBD localized cream and a 2% CBD/1% CBG transdermal gel that leverage Avicanna’s proprietary deep tissue delivery technology. The formulations are produced in Colombia using USDA organic hemp cultivated by Avicanna’s Santa Marta Golden Hemp subsidiary and are available via replaycbd.com and select retail outlets this month.
The move extends a biopharma-built cannabinoid platform into the U.S. consumer wellness aisle, testing whether pharmaceutical-grade formulation discipline and IP around delivery can command differentiation in an oversupplied CBD market. It also raises a pivotal question for pharma-adjacent cannabinoid players: can scientifically structured topicals, framed around athlete needs and consistent manufacturing, build a premium segment that creates credible evidence assets for future prescription pathways?
Timing matters. HCPs are fielding sustained patient demand for non-opioid, non-NSAID options for localized discomfort, yet CBD products have suffered from variability, unclear dosing, and mixed regulatory signals. A THC-free, standardized topical with defined CBD and CBG concentrations and a transdermal approach could shift the dialogue from anecdotes to data, particularly in sports medicine, orthopedics, and physical therapy. While broad third-party reimbursement is unlikely for wellness products, employer-sponsored programs, team procurement, and workers’ compensation channels may experiment if usability and safety are clear and outcomes can be tracked. For competitors, the message is that the commodity CBD era is ending; delivery science, supply chain provenance, and post-market evidence are becoming table stakes.
Strategically, Avicanna is aligning multiple pillars: vertically integrated hemp sourcing, Colombian cost advantages in GMP-like production, and a scientific platform that already spans medical cannabis in Canada and Latin America. A U.S. wellness presence can generate cash flow, retail relationships, and real-world usage data while de-risking longer-horizon prescription cannabinoid ambitions. It also positions the company near potential 505(b)(2) routes in topical analgesia if future regulatory clarity emerges, even if CBD/CBG as active ingredients remain fraught in the U.S. today. The transdermal know-how itself is transferable to other actives, creating optionality beyond cannabinoids.
Regulatory context remains the wildcard. FDA has not established a clear dietary supplement pathway for CBD and continues to police drug-like claims, but cosmetic topicals with compliant positioning have navigated retail placements. State patchworks add complexity. Success will hinge on disciplined claims, validation of batch consistency, and the generation of pragmatic evidence that resonates with HCPs and retail category managers alike. For Medical Affairs teams, there is an opening to design pragmatic registries in sports settings, explore drug–drug interaction education given cannabinoid metabolism pathways, and publish real-world outcomes that elevate the category’s credibility without overstepping regulatory boundaries.
What to watch next: the pace of national retail uptake beyond niche e-commerce, publication of any observational data on pain scores, recovery timelines, or return-to-play outcomes, and whether Avicanna leverages its athlete channel into payer-adjacent partnerships such as workers’ comp networks or employer wellness formularies. The strategic hinge is whether a wellness beachhead can mature into a defensible data and technology asset that accelerates a prescription-grade pipeline, or whether ongoing regulatory ambiguity and price compression push Avicanna to prioritize B2B ingredient supply and out-licensing of its transdermal platform.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
